Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

This is a an open-label, non-inferiority, multicenter, randomized phase III trial aimed to explore the efficacy and safety of shrinking the anterior border of CTV2 in nasopharyngeal carcinoma patients without tumor invasion into the posterior nasal aperture.

NCT Number	NCT07072000
Lead Sponsor	Hai-Qiang Mai,MD,PhD Collaborators: First People's Hospital of Foshan, Affiliated Hospital of Guangdong Medical University, The Wuzhou Red Cross Hospital, Fourth Affiliated Hospital of Guangxi Medical University, Zhongshan City People 's Hospital
Conditions	Nasopharyngeal Cancinoma (NPC)
Enrollment	550 participants
Start Date	2025-08-01
Primary Completion	2030-07-31 (estimated)
Study Completion	2032-07-31 (estimated)
Updated on ClinicalTrials.gov	2025-07-18